





XENICAL® (orlistat) and XELODA® (capecitabine): An important message from Roche

Dear Pharmacist:

As you know, Roche Laboratories introduced XENICAL this year. During the first 10 weeks, over 380,000 total prescriptions have been filled for XENICAL. In addition, 23,000 prescriptions have been filled this year for XELODA, another Roche product.

There have been 2 reports of dispensing errors involving XELODA and XENICAL. In one instance XELODA was dispensed instead of XENICAL, and in the other case, XENICAL was dispensed in place of XELODA. XELODA is an oral antineoplastic agent, and XENICAL is an oral antiobesity agent. To prevent dispensing errors involving XENICAL and XELODA in your pharmacy, please review both these medications' respective appearances, indications and dosages.

<i>Brand name (generic name)</i>	XENICAL® orlistat	XELODA® capecitabine
<i>Appearance</i>	Dark blue, 120-mg capsules - bottles of 90 	Light peach, 150-mg tablets - bottles of 120, and peach, 500-mg - bottles of 240 
<i>Pronunciation</i>	ZEN-I-cal	zeh-LOE-duh

Please see enclosed complete product information for both XENICAL and XELODA.

<i>Brand name (generic name)</i>	XENICAL® orlistat	XELODA® capecitabine
<i>Indication</i>	XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥ 30 kg/m ² or ≥ 27 kg/m ² in the presence of other risk factors (eg, hypertension, diabetes, dyslipidemia).	XELODA is indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, eg, patients who have received cumulative doses of 400 mg/m ² of doxorubicin or doxorubicin equivalents. This indication is based on a demonstration of a response rate. No results are available from controlled trials that demonstrate a clinical benefit resulting from treatment, such as improvement in disease-related symptoms, disease progression, or survival.
<i>Dosage and administration</i>	One 120-mg capsule tid with each main meal containing fat.	2500 mg/m ² administered orally in two divided doses daily with food for 2 weeks, followed by a 1-week rest period, given as 3-week cycles.

Remember when dispensing...

- XENICAL is dosed tid while XELODA is q12h
- XENICAL is bottled in one size of 90 capsules while XELODA offers two bottle sizes of 120 or 240 tablets
- XENICAL is available in a dark blue capsule while XELODA is available in a peach or light peach tablet
- If the prescription is illegible, please confirm it by telephoning the physician's office
- Should you have any questions about XENICAL or XELODA, please call Roche at 1-800-887-3900

Yours truly,

((Signature))

Muna Bitar, PharmD
Product Services Manager

Please see enclosed complete product information for both XENICAL and XELODA.